Dr. Brentjens Discusses the Goal of Armored CAR T Cells – OncLive
The Pharma Letter |
Dr. Brentjens Discusses the Goal of Armored CAR T Cells
OncLive Renier Brentjens, MD, PhD, associate professor, chief, Cellular Therapeutics Center, Memorial Sloan Kettering Cancer Center, discusses the goal of armored chimeric antigen receptor (CAR) T cells. Patients who relapse after treatment with CAR T-cell … Memorial Sloan Kettering provides roadmap for successful CAR–T cell program |
